Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;8(4):1725-1730.
doi: 10.3892/ol.2014.2351. Epub 2014 Jul 15.

DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepatocellular carcinoma: A meta-analysis

Affiliations

DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepatocellular carcinoma: A meta-analysis

Wenyan Li et al. Oncol Lett. 2014 Oct.

Abstract

The arginine194tryptophan (Arg194Trp) polymorphism in the X-ray repair cross-complementing group 1 (XRCC1) gene has been reported to be associated with hepatocellular carcinoma (HCC), however, the results from previous studies are conflicting. The present study aimed to investigate the association between the XRCC1 Arg194Trp polymorphism and the risk of HCC, using a meta-analysis of previously published studies. PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Google Scholar (http://scholar.google.co.uk/) and the China National Knowledge Infrastructure databases (http://www.cnki.net/) were systematically searched to identify relevant studies published prior to October 2013. A meta-analysis was performed to examine the association between the Arg194Trp gene polymorphism and the susceptibility to HCC. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. The meta-analysis consisted of six case-control studies that included 1,451 HCC cases and 1,398 healthy controls. Meta-analysis results based on all the studies showed no significant association between the XRCC1 Arg194Trp gene polymorphism and the risk of HCC (Trp/Trp vs. Arg/Arg: OR, 1.17; 95% CI, 0.89-1.55; Trp/Trp vs. Arg/Trp: OR, 0.94; 95% CI, 0.59-1.51; dominant model: OR, 0.97; 95% CI, 0.63-1.49; recessive model: OR, 1.22; 95% CI, 0.89-1.67). In the subgroup analysis, three studies with sample sizes of >300 produced similar results that indicated that the Arg194Trp gene polymorphism had no association with an increased or decreased risk of HCC. The pooled ORs were not markedly different following the exclusion of two studies deviating from the Hardy-Weinberg equilibrium in the control group, which indicated the reliability of the meta-analysis results. In conclusion, the XRCC1 Arg194Trp polymorphism may not be a risk or protective factor for HCC. Further large and well-designed studies are required to confirm these results.

Keywords: X-ray repair cross-complementing group 1; gene polymorphism; hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study selection based on the inclusion and exclusion criteria. Arg, arginine; Trp, tryptophan.
Figure 2
Figure 2
Forest plots of the Arg194Trp gene polymorphism in the hepatocellular carcinoma vs. normal control and subgroup analyses. HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; Arg, arginine; Trp, tryptophan.

Similar articles

Cited by

References

    1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer. 1975–2001, with a special feature regarding survival. Cancer. 2004;101:3–27. - PubMed
    1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–S16. - PubMed
    1. Parkin DM, Bray FI, Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:S4–S66. - PubMed
    1. Hu Z, Zhao W. Novel insights into the molecular mechanisms of α-fetoprotein expression and malignant phenotypes of hepatocellular carcinoma. Cell Mol Immunol. 2012;9:7–8. - PMC - PubMed
    1. Karabork A, Kaygusuz G, Ekinci C. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract. 2010;206:572–577. - PubMed